It has been shown that lymphangiogenesis is a critical initiator of tumor lymphatic metastasis.[10, 11] Accumulating evidence has demonstrated that upregulation of fibroblast growth factor 2 (FGF2), a lymphangiogenic growth factor, positively correlates with regional LN metastasis and poor survival in multiple human malignancies including liver cancer,[12] melanoma[13] and CSCC.[14] Previous research has indicated that inhibition of FGF2‐mediated signaling pathways using siRNA, anti‐FGF2 antibodies, or “FGF ligand trap” neutralizing antibodies can halt metastatic spread of human malignancies. The gene discussed is FGF2; the disease is melanoma.